Recent Updates
Recently added Catalysts
AMLX Positive Sentiment

Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock

Key Takeaway: Amylyx Pharmaceuticals has announced a public offering of $350 million in common stock. The company also plans to give underwriters a 30-day option to buy an additional $52.5 million in shares. This move aims to enhance its financial resources for future initiatives.

Market Sentiment Analysis

POSITIVE FACTORS

  • Amylyx Pharmaceuticals is raising significant capital through a public offering.
  • The offering could strengthen the company's financial position.
  • The underwriters have the option to purchase additional shares, indicating confidence.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+167%
120-day peak, hindsight
Typical move
4.4%
average across 3 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
AMX0035
Phase 3 · Amyotrophic Lateral Sclerosis

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of $350.0 million of shares of its common stock. In addition, Amylyx intends to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the shares of common stock are bein

Frequently Asked Questions

What is the amount of the proposed public offering?

Amylyx Pharmaceuticals has announced a proposed public offering of $350 million.

What additional option do underwriters have?

Underwriters have a 30-day option to purchase up to an additional $52.5 million in shares.

What is the purpose of the public offering?

The public offering aims to enhance Amylyx Pharmaceuticals' financial resources.

Last updated: Aug 18, 2026